(Q39798595)

14 September 2017

title

Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations (English)

1 reference

non-small-cell lung carcinoma

14 September 2017

main subject

1 reference

In Hae Park

1

1 reference

14 September 2017

Jin Young Kim

series ordinal

2

1 reference

14 September 2017

Jae In Jung

series ordinal

3

1 reference

14 September 2017

Ji-Youn Han

series ordinal

4

1 reference

14 September 2017

publication date

17 September 2009

1 reference

Investigational New Drugs

14 September 2017

published in

1 reference

14 September 2017

volume

28

1 reference

14 September 2017

issue

6

1 reference

14 September 2017

page(s)

791-799

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-009-9319-4

14 September 2017

exact match

0 references

cites work

K-ras gene mutation enhances motility of immortalized airway cells and lung adenocarcinoma cells via Akt activation: possible contribution to non-invasive expansion of lung adenocarcinoma.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-009-9319-4

Pro-apototic and anti-apoptotic effects of tumor necrosis factor in tumor cells. Role of nuclear transcription factor NF-kappaB.

21 January 2018

1 reference

12 December 2020

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

1 reference

12 December 2020

Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors

1 reference

12 December 2020

Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design

1 reference

12 December 2020

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

12 December 2020

Lovastatin induces apoptosis of k-ras-transformed thyroid cells via inhibition of ras farnesylation and by modulating redox state

1 reference

12 December 2020

Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor

1 reference

12 December 2020

Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: retrospective analysis of 575 Korean patients

1 reference

12 December 2020

The Ras superfamily at a glance

1 reference

12 December 2020

Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial

1 reference

12 December 2020

Increasing complexity of Ras signaling.

1 reference

12 December 2020

Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status

1 reference

12 December 2020

Statins and cancer prevention

1 reference

12 December 2020

Phosphatidylinositol-3-OH kinase as a direct target of Ras

1 reference

12 December 2020

Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells.

1 reference

12 December 2020

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

12 December 2020

Untangling the ErbB signalling network

1 reference

12 December 2020

Structural mechanism for statin inhibition of HMG-CoA reductase

1 reference

12 December 2020

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

1 reference

12 December 2020

Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells.

1 reference

12 December 2020

The statins as anticancer agents

1 reference

12 December 2020

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

12 December 2020

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

1 reference

12 December 2020

Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?

1 reference

12 December 2020

HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis

1 reference

12 December 2020

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

1 reference

12 December 2020

10.1007/S10637-009-9319-4

Identifiers

DOI

1 reference

14 September 2017

1 reference